Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Initiation rates for ADM GLP-1 RA are about the same in September 2025, relative to June 2025 (+2.0%)
Launching with Affirm is an important step in advancing FuturHealths mission to make personalized, science-backed wellness more accessible at scale, said FuturHealth co-founder & CEO Luke Mahoney
Pipeline Activity The pipeline for GLP-1 and related metabolic disease treatments is extremely active
Endocrinology (2019) 160:278799
Early placebo-controlled trials hinted that tirzepatide might produce greater average weight loss than semaglutide
US$ 20.40
US$ 21.64
US$ 21.46
US$ 24.38
US$ 29.29
